论文部分内容阅读
目的探讨辉瑞液明珠联合托吡卡胺治疗假性近视的科学性及临床应用效果。方法124眼假性近视眼随机分为两组:A组为辉瑞液明珠联合0.5%托吡卡胺治疗组;B组为单用0.5%托吡卡胺治疗组。治疗30d后比较两组视力及视疲劳症状恢复情况,应用χ2检验分析两组疗效差异。所有统计数据在SPSS11.0软件包中处理。结果A组治愈45眼,有效12眼,有效率为91.93%;B组治愈22眼,有效10眼,有效率为51.61%。根据χ2检验,A组优于B组(P<0.05,χ2=5.68)。结论辉瑞液明珠联合0.5%托吡卡胺治疗组其疗效明显优于单纯应用0.5%托吡卡胺治疗组,其疗效可靠,且在服药期间均未出现任何不良反应,故此法可作为防止假性近视发展成为真性近视的预防性用药。
Objective To investigate the scientific and clinical application of Pfizer Pearl combined with tropicamide in the treatment of pseudo-myopia. Methods One hundred and twenty-four eyes of pseudo-myopia were randomly divided into two groups: group A was treated with Pfizer Pearl combined with 0.5% tropicamide and group B was treated with 0.5% tropicamide alone. After 30 days of treatment, visual acuity and visual fatigue recovery were compared between the two groups. Chi-square test was used to analyze the difference in therapeutic effect between the two groups. All statistics are processed in the SPSS11.0 package. Results In group A, 45 eyes were cured, 12 eyes were effective, and the effective rate was 91.93%. In group B, 22 eyes were cured and 10 eyes were effective. The effective rate was 51.61%. According to χ2 test, group A was better than group B (P <0.05, χ2 = 5.68). Conclusion The efficacy of Pfizer Pearl combined with 0.5% tropicamide was significantly better than that of 0.5% tropicamide alone, and its efficacy was reliable and no adverse reactions occurred during the medication. Therefore, this method can be used as a preventive against false Development of sexual myopia as a real myopia preventive medication.